NATURE OF OPERATIONS	9 Months Ended
Sep. 30, 2025
NATURE OF OPERATIONS
NATURE OF OPERATIONS	NOTE 1 - NATURE OF OPERATIONS Transuite.Org Inc. ("TRSO") is a Nevada-incorporated artificial intelligence solutions provider founded on June 15, 2018, with its common shares publicly traded on the OTCQB market under the symbol TRSO. As an SEC-reporting issuer, the company maintains a steadfast commitment to delivering sustainable value to shareholders through innovative AI technologies. Led by top AI scientists and powered by elite research team, TRSO has developed the world-leading AI Social Agent platform. This groundbreaking technology integrates multimodal intelligence, real-time translation, deviation correction learning, knowledge fusion, and complex reasoning capabilities - creating the most creative AI "super employees" that deliver extraordinary value to enterprises. As the global pioneer in "AI Workforce as a Service" (AWaaS), our innovative model enables enterprises to either rent or purchase AI employees as permanent knowledge assets, setting the global standard for enterprise AI adoption. TRSO has established itself as a leader in AI-driven business solutions, offering pioneering AI Social Agent platforms for global enterprises. We are dedicated to making AI workforce deployment more accessible and efficient, enabling businesses to meet growing demands for intelligent automation. Our platform allows enterprises to rapidly deploy industry-specific AI social agents that integrate natively with major global platforms including WhatsApp, Telegram, and WeChat. These advanced agents deliver 24/7, hyper-realistic customer interactions while automating complex business processes, ultimately driving superior operational outcomes. Our mission centers on empowering organizations to build their AI workforce, enhance efficiency, and transform customer engagement through our revolutionary technology. Building upon our AI social agent foundation, TRSO is developing a comprehensive AI ecosystem that combines multimodal intelligence, seamless social platform integration, and sophisticated business process automation. This strategic expansion positions the company at the vanguard of AI innovation, addressing evolving enterprise needs across multiple sectors including healthcare, e-commerce, and education. The company benefits from the leadership of an internationally recognized team with roots in Tsinghua University, bringing more than ten years of specialized expertise in artificial intelligence, machine learning, natural language processing, and enterprise-grade solutions. Through our proprietary technologies and deep experience in large-scale AI model implementation, TRSO develops transformative solutions that help businesses successfully navigate the AI revolution while delivering concrete, measurable value to users worldwide. On November 24, 2024, the Company and other founders formed Goldfinch Group Holdings Ltd. In which the Company holds a 70% controlling interest. On August 8, 2025, the Company entered into a share exchange agreement with Fidelity World Holdings Ltd. for the acquisition of the remaining 30% equity interest in Goldfinch Group Holdings Ltd. through the issuance of 3,000,000 restricted common shares at $2.00 per share with a fair of $6,000,000. Upon the completion of the transaction, the Goldfinch Group Holdings Ltd. become wholly owned subsidiary of the Company. On August 25, 2025, the Company entered into a share exchange agreement with Crestar Holdings Ltd., wholly owned subsidiary of Goldfinch Group Holdings Ltd., and Hailiang Li for the acquisition of 51% equity interest in SolanAI Global Ltd., a Hong Kong AI technology company, through the issuance of 10,000,000 restricted common shares at $1.25 per share with a fair value of $12,500,000 as initial consideration. The Company may issue up to 5,000,000 additional shares based on independent SolanAI’s valuation completed within 120 days, subject to Board approval and additional SEC disclosure. On August 25, 2025, the Company completed the acquisition of 51% of SolanAI. On September 15, 2025, the Company entered into a Letter of Intent (“LOI”) with Fujian Wochong Intelligent Technology Co., Ltd. (“Wochong”) outlining a proposed transaction for the acquisition of 51% of the equity interest in Wochong through the issuance of common stock. The LOI stipulates that the transaction will be executed based on the mutually agreed valuation of Wochong, which is to be determined upon completion of due diligence. The agreement is subject to several conditions, including satisfactory due diligence results, approval by the boards of directors of both companies, the absence of any material adverse changes, and obtaining all necessary third-party consents. The LOI includes mutual confidentiality provisions and grants either party the right to terminate the agreement in writing should the due diligence results prove unsatisfactory. On September 26, 2025, the Company entered into a Letter of Intent (“LOI”) with SYD GOLDX PTY LTD (“SGX”) outlining a proposed transaction for the acquisition of 51% of the equity interest in SGX, an Australian licensed Digital Currency Exchange, through the issuance of common stock. The LOI provides that the parties will negotiate in good faith to enter into a definitive agreement, subject to satisfactory completion of due diligence, negotiation of final terms, approval by the boards of directors of both companies, and other customary conditions. The LOI includes mutual confidentiality provisions and grants either party the right to terminate the agreement in writing should the due diligence results prove unsatisfactory. On September 30, 2025, the Company entered into a share exchange agreement with Crestar Holdings Ltd., wholly owned subsidiary of Goldfinch Group Holdings Ltd., and Hailiang Li for the acquisition of 100% equity interest in Xirangsheng (Shenzhen) Health Technology Co., Ltd. (“XRS”), an innovative enterprise based on the combination of AI Social Agent and Traditional Chinese Medicine, through the issuance of 10,000,000 restricted common shares at $0.17 per share with a fair value $1,700,000 as initial consideration. The Company may issue additional shares within 60 days after receipt of the independent valuation of XRS upon terms agreed on the Agreement, subject to Board approval and compliance with applicable securities laws. On September 30, 2025, the Company completed the acquisition of 100% of XRS.

NATURE OF OPERATIONS

9 Months Ended

Sep. 30, 2025

NOTE 1 - NATURE OF OPERATIONS

Transuite.Org Inc. ("TRSO") is a Nevada-incorporated artificial intelligence solutions provider founded on June 15, 2018, with its common shares publicly traded on the OTCQB market under the symbol TRSO. As an SEC-reporting issuer, the company maintains a steadfast commitment to delivering sustainable value to shareholders through innovative AI technologies.

Led by top AI scientists and powered by elite research team, TRSO has developed the world-leading AI Social Agent platform. This groundbreaking technology integrates multimodal intelligence, real-time translation, deviation correction learning, knowledge fusion, and complex reasoning capabilities - creating the most creative AI "super employees" that deliver extraordinary value to enterprises. As the global pioneer in "AI Workforce as a Service" (AWaaS), our innovative model enables enterprises to either rent or purchase AI employees as permanent knowledge assets, setting the global standard for enterprise AI adoption.

TRSO has established itself as a leader in AI-driven business solutions, offering pioneering AI Social Agent platforms for global enterprises. We are dedicated to making AI workforce deployment more accessible and efficient, enabling businesses to meet growing demands for intelligent automation. Our platform allows enterprises to rapidly deploy industry-specific AI social agents that integrate natively with major global platforms including WhatsApp, Telegram, and WeChat. These advanced agents deliver 24/7, hyper-realistic customer interactions while automating complex business processes, ultimately driving superior operational outcomes. Our mission centers on empowering organizations to build their AI workforce, enhance efficiency, and transform customer engagement through our revolutionary technology.

Building upon our AI social agent foundation, TRSO is developing a comprehensive AI ecosystem that combines multimodal intelligence, seamless social platform integration, and sophisticated business process automation. This strategic expansion positions the company at the vanguard of AI innovation, addressing evolving enterprise needs across multiple sectors including healthcare, e-commerce, and education.

The company benefits from the leadership of an internationally recognized team with roots in Tsinghua University, bringing more than ten years of specialized expertise in artificial intelligence, machine learning, natural language processing, and enterprise-grade solutions. Through our proprietary technologies and deep experience in large-scale AI model implementation, TRSO develops transformative solutions that help businesses successfully navigate the AI revolution while delivering concrete, measurable value to users worldwide.

On November 24, 2024, the Company and other founders formed Goldfinch Group Holdings Ltd. In which the Company holds a 70% controlling interest.

On August 8, 2025, the Company entered into a share exchange agreement with Fidelity World Holdings Ltd. for the acquisition of the remaining 30% equity interest in Goldfinch Group Holdings Ltd. through the issuance of 3,000,000 restricted common shares at $2.00 per share with a fair of $6,000,000. Upon the completion of the transaction, the Goldfinch Group Holdings Ltd. become wholly owned subsidiary of the Company.

On August 25, 2025, the Company entered into a share exchange agreement with Crestar Holdings Ltd., wholly owned subsidiary of Goldfinch Group Holdings Ltd., and Hailiang Li for the acquisition of 51% equity interest in SolanAI Global Ltd., a Hong Kong AI technology company, through the issuance of 10,000,000 restricted common shares at $1.25 per share with a fair value of $12,500,000 as initial consideration. The Company may issue up to 5,000,000 additional shares based on independent SolanAI’s valuation completed within 120 days, subject to Board approval and additional SEC disclosure. On August 25, 2025, the Company completed the acquisition of 51% of SolanAI.

On September 15, 2025, the Company entered into a Letter of Intent (“LOI”) with Fujian Wochong Intelligent Technology Co., Ltd. (“Wochong”) outlining a proposed transaction for the acquisition of 51% of the equity interest in Wochong through the issuance of common stock. The LOI stipulates that the transaction will be executed based on the mutually agreed valuation of Wochong, which is to be determined upon completion of due diligence. The agreement is subject to several conditions, including satisfactory due diligence results, approval by the boards of directors of both companies, the absence of any material adverse changes, and obtaining all necessary third-party consents. The LOI includes mutual confidentiality provisions and grants either party the right to terminate the agreement in writing should the due diligence results prove unsatisfactory.

On September 26, 2025, the Company entered into a Letter of Intent (“LOI”) with SYD GOLDX PTY LTD (“SGX”) outlining a proposed transaction for the acquisition of 51% of the equity interest in SGX, an Australian licensed Digital Currency Exchange, through the issuance of common stock. The LOI provides that the parties will negotiate in good faith to enter into a definitive agreement, subject to satisfactory completion of due diligence, negotiation of final terms, approval by the boards of directors of both companies, and other customary conditions. The LOI includes mutual confidentiality provisions and grants either party the right to terminate the agreement in writing should the due diligence results prove unsatisfactory.

On September 30, 2025, the Company entered into a share exchange agreement with Crestar Holdings Ltd., wholly owned subsidiary of Goldfinch Group Holdings Ltd., and Hailiang Li for the acquisition of 100% equity interest in Xirangsheng (Shenzhen) Health Technology Co., Ltd. (“XRS”), an innovative enterprise based on the combination of AI Social Agent and Traditional Chinese Medicine, through the issuance of 10,000,000 restricted common shares at $0.17 per share with a fair value $1,700,000 as initial consideration. The Company may issue additional shares within 60 days after receipt of the independent valuation of XRS upon terms agreed on the Agreement, subject to Board approval and compliance with applicable securities laws. On September 30, 2025, the Company completed the acquisition of 100% of XRS.